Gain of 1q is a marker of poor prognosis in Wilms' tumors.

Genes, chromosomes & cancer

PubMedID: 24038759

Segers H, van den Heuvel-Eibrink MM, Williams RD, Van Tinteren H, Vujanic G, Pieters R, Pritchard-Jones K, Bown N, Children's Cancer and Leukaemia Group and the UK Cancer Cytogenetics Group. Gain of 1q is a marker of poor prognosis in Wilms' tumors. Genes Chromosomes Cancer. 2013;.
Wilms' tumor (WT) trials aim to better tailor treatment intensity to the risk of relapse and death. Currently, stage, histology, age (< or?>?24 months), and combined loss of heterozygosity at 1p and 16q in chemotherapy-naïve WTs are the only risk factors used for treatment stratification. However, they predict only less than one-third of all relapsing patients, implying that other factors are involved in treatment failure. Previous studies have associated 1q gain with adverse outcome. Therefore, in this study, the role of 1q gain and other common cytogenetic aberrations (CAs) in WTs was investigated and related to follow-up data from patients with WT treated in the United Kingdom; 19% (64/331) had 1q gain. Gain of 1q was significantly associated with 16q loss (P?